PDCD1 and neoplasm: Pembrolizumab and nivolumab, both mAb ICIs that target PD-1, have shown promising, durable anti-tumour results in MSI-H/dMMR CRC patients, and have led to FDA approval for both drugs for this subset of patients within the last few years to be used as a salvage therapy.154